Triplet systemic therapy for hormone-sensitive prostate cancer: a critical review with a multidisciplinary approach

Triplet systemic therapy for hormone-sensitive prostate cancer: a critical review with a multidisciplinary approach

This article aims to critically evaluate the evidence for triplet therapy consisting of androgen deprivation therapy (ADT), docetaxel and a second-generation androgen receptor pathway inhibitor ([ARPI]; abiraterone, enzalutamide, darolutamide or apalutamide) in patients with metastatic hormone-sensi...

Full description

Saved in:
Bibliographic Details
Main Authors: Almudena Zapatero, Teresa Alonso-Gordoa, Alfredo Rodríguez Antolín, Felipe Couñago, Noelia Sanmamed, Mario Domínguez Esteban, Marta López Valcárcel, Ray Manneh, Ángel Borque-Fernando, Nuria Sala González, Pablo Maroto
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-07-01
Series:Oncology Reviews
Subjects:
androgen deprivation therapy
androgen receptor-targeted therapy
docetaxel
hormone-sensitive prostate cancer
metastatic prostate cancer
Online Access:https://www.frontiersin.org/articles/10.3389/or.2025.1599292/full
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items